Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Psychiatry
Main Authors: Pilon, Dominic, Muser, Erik, Lefebvre, Patrick, Kamstra, Rhiannon, Emond, Bruno, Joshi, Kruti
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457548/
https://ncbi.nlm.nih.gov/pubmed/28576133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12888-017-1358-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados